Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/33169
MCCOY CELL LINE AS A POSSIBLE MODEL CONTAINING CD4+ RECEPTORS FOR THE STUDY OF HIV-1 REPLICATION
Autor(es)
Afiliação
Instituto Adolfo Lutz. São Paulo, SP, Brasil.
Instituto Adolfo Lutz. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Instituto Adolfo Lutz. São Paulo, SP, Brasil.
Fundação Pró-Sangue/Hemocentro. São Paulo, SP, Brasil.
Instituto Adolfo Lutz. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Instituto Adolfo Lutz. São Paulo, SP, Brasil.
Fundação Pró-Sangue/Hemocentro. São Paulo, SP, Brasil.
Resumo em Inglês
Several studies have recently shown the use of recombinant rabies virus as potential vector-viral vaccine for HIV-1. The sequence homology between gp 120 and rabies virus glycoprotein has been reported. The McCoy cell line has therefore been used to show CD4+ or CD4+ like receptors. Samples of HIV-1 were isolated, when plasma of HIV-1 positive patients was inoculated in the McCoy cell line. The virus infection was then studied during successive virus passages. The proteins released in the extra cellular medium were checked for protein activity, by exposure to SDS Electrophoresis and blotting to nitro-cellulose filter, then reacting with sera of HIV positive and negative patients. Successive passages were performed, and showed viral replication, membrane permeabilization, the syncytium formation, and the cellular lysis (cytopathic effect). Flow cytometry analysis shows clear evidence that CD4+ receptors are present in this cell line, which enhances the likelihood of easy isolation and replication of HIV. The results observed allow the use of this cell line as a possible model for isolating HIV, as well as for carrying out studies of the dynamics of viral infection in several situations, including exposure to drugs in pharmacological studies, and possibly studies and analyses of the immune response in vaccine therapies.
Compartilhar